|

Siltuximab Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: Anti-IL-6 Chimeric Monoclonal Antibody, CNTO 328, CNTO-328, Sylvant, cCLB8

Other1 trial

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Phase 2

Boston, Massachusetts1 trial

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Massachusetts General Hospital Cancer Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Cleveland, Ohio1 trial

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Phase 1

Columbus, Ohio1 trial

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.